NURECA LIMITED (NURECA): Financials & Fundamentals History

Share price

Closing priceAdjusted for splits and bonus issues.

3M1Y3YAll

₹302.1 latest close · +31.9% over the last 90 sessions

₹302.1 month-end · +4.3% over 12 months

₹302.1 month-end · −15.9% over 3 years

₹302.1 month-end · −55.4% since Feb '21

52-week range ₹204.00 to ₹376.00 · 1-year volatility 46.9%

Was the rally earned?

-80%share price, 5 yearsEarnings-driven

Mostly earnings.

Per-share earnings took off 154 points, while the multiple moved less (P/E 32.0x to 141.8x).
The share count fell 3%.

Net profit growth-155 ptsNet profit fell about 96%, which lowers the price.

P/E change+74 ptsThe P/E rose from 32.0x to 141.8x, which lifts the price.

Share count change+1 ptsShare count fell 3%, which lifts the price.

What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Not shown for 1 year and 3 years: earnings were negative at one end, or there is not enough history.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with INVENTURUS KNOWLEDGE SOLU

How rough has the ride been?

Maximum drawdown-90.3%not yet recovered

1-year volatility46.9%annualised

Drawdown from peak

Largest drawdowns

-90.3% (2021-10 peak to 2026-03 low, not yet recovered)

-18.9% (2021-03 peak to 2021-03 low, recovered 2021-04)

-18.1% (2021-08 peak to 2021-08 low, recovered 2021-10)

Is it expensive against its own past and its peers?

141.8xP/E todayNear its historic high

Against its own history90th percentile

CheapestMedian 29.4xDearest

Usual range 6.9x to 147.9x since 2021-02.

Against Health Technology141.8x vs 37.0x

This company

141.8x

Sector median

37.0x

283% above the Health Technology median.

P/EP/BP/S

P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

ROCE13th▲ 5 pts vs a year ago
Op. margin16th▲ 8 pts vs a year ago
Revenue growth74th▼ 16 pts vs a year ago
EPS growth9th▼ 35 pts vs a year ago
Debt/equity ↓91st▲ 5 pts vs a year ago
Cash cycle ↓47thflat vs a year ago
P/E ↓5th
12M momentum47th▼ 24 pts vs a year ago

Rank history

ROCE

Op. margin

Revenue growth

EPS growth

Debt/equity ↓

Cash cycle ↓

P/E ↓

12M momentum

Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26

Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~25%annual earnings growth implied by the price

At a P/E of 45.3x, the price would imply about 25.1%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.

Fewer than six years of annual earnings are available, which is too little to measure delivered growth.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov: ₹302.10
P/E: 141.8x
ROCE: 2.0%
Market Cap: ₹286 cr
Revenue (TTM): ₹153 cr
P/S: 1.9x
P/B: 1.6x
ROE: 1.1%
Operating Margin: 6.1%
Debt / Equity: 0.0x
Promoter Holding: 68.1%
12M Momentum: 4.3%

52-week range

₹204.00₹376.00

57% of the way from its 52-week low to its high

Price risk

1Y volatility

46.9%

Beta vs sector

1-year daily

0.58

Balance sheet & cash

Interest cover

operating profit ÷ interest

6.6x

Cash from profit, 3Y

operating cash flow ÷ net profit

0.31x

low

Share count, 1Y

unchanged

Are profits backed by cash?

4 of 6checks within range2 beyond a threshold

Other income reliance136%Beyond threshold

Other income as a share of pre-tax profit (trailing twelve months): 136.1%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate22%Within range

Median quarterly effective tax rate over about 2.5 years: 21.9%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion—Not enough data

Not enough reported data to compute this.

Free cash flow1 of 5 yrsBeyond threshold

Fiscal years with positive free cash flow in the last 5: 1. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history+10 daysWithin range

Debtor days are above the median of the previous three fiscal years by 10 days (24 vs 14). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress0% of fixed assetsWithin range

Capital work-in-progress is 0% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days-4 days / 2 yrsWithin range

Days payable changed by -4 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

Over 3 years, promoters added 4.9 pts.
The number of shareholders fell from 52,255 to 33,979 (-35%) between Sep 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupSep '23Jun '26Change

Promoters63.2%68.1%+4.9 pts

FIIs0.1%0.1%0.0 pts

DIIs0.0%0.2%+0.2 pts

Public and others36.7%31.6%-5.1 pts

Number of shareholders

33,979shareholders-35% since Sep '23

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−8.1%typical 12-month return vs the marketNot meaningfully different from the base rate

We found 50 past situations where a non-financial company looked like NURECA LIMITED today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
Over the following 12 months the middle half of them returned −32% to +18% vs the market, against −3% for all non-financial companies in the same months.
The gap against the base rate (−5.0%, 80% range −11.3% to +2.6%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 2 beyond the range shown, drawn at the edge

Similar setups' median

−8.1%

All companies' median

−3.1%

Beat the market

44% vs 47%

50 past situations · 50 companies · 36 months · 2020–2025

The closest matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
ANIKINDS Distribution Services	Aug 2025	86x	1%	+17%	−29%	−54%
URJA Electronic Technology	Nov 2021	260x	2%	+123%	−18%	+30%
BIOFILCHEM Health Technology	Apr 2024	207x	5%	+53%	−6%	−38%
LOTUSEYE Health Services	Sep 2020	59x	5%	+36%	−20%	−1%
DENORA Electronic Technology	May 2020	57x	4%	−29%	−33%	+19%

Show the other 3 matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
MAHEPC Producer Manufacturing	Apr 2025	160x	3%	+1%	−20%	−21%
PILITA Producer Manufacturing	Feb 2024	112x	6%	+108%	−13%	−10%
TDPOWERSYS Producer Manufacturing	Mar 2020	85x	3%	−29%	−52%	−3%

How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: drawdown from 12-month high, 12-month momentum and P/S. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to NURECA LIMITED. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

Feature	Weight	Non-financial	Financial
P/E	1	yes	yes
P/S	1	yes	—
P/B	1	—	yes
ROCE	1	yes	—
operating margin	1	yes	—
ROE	1	—	yes
debt/equity	0.75	yes	—
interest cover	0.5	yes	—
revenue growth	0.75	yes	yes
12-month momentum	1	yes	yes
drawdown from 12-month high	0.75	yes	yes
size	0.75	yes	yes
volatility	0.5	yes	yes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What changed?

13 events since Jun '21

2026
JunPromoterPromoter holding rose 3.1 pts to 68.1% (largest rise in the history since 2019-01).
JunValuationP/E crossed above the 90th percentile of its own history to date (1826.2x).
MarPriceFell 90% from the Oct 2021 peak to the Mar 2026 low.
2025
DecResultsEPS (TTM) turned positive.
DecValuationP/E crossed above the 90th percentile of its own history to date (124.7x).
2023
JunResultsEPS (TTM) turned negative.
JunPeer rankSlipped to the bottom quartile of Health Technology on ROCE (from the top quartile).
JunDividendDividend payout cut from 7% to 0% of profit.

Show 5 earlier events

2022
JunResultsRevenue (TTM) reached a new high of ₹256 cr.
JunPeer rankMoved into the 3rd quartile of Health Technology on EPS growth (from the bottom quartile).
FebDebtDebt / equity halved over 12 months to 0.02x.
FebSharesShare count is up 200.0% over 12 months.
2021
JunDividendStarted paying a dividend (payout 4% of profit).

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history70 months · 2021-02 to 2026-11

Month	P/E	Revenue (TTM)	ROE	ROCE	Debt / Equity
2026-11	141.8x	₹153 cr	1.1%	2.0%	0.0x
2026-10	137.9x	₹153 cr	1.1%	2.0%	0.0x
2026-09	172.1x	₹153 cr	1.1%	2.0%	0.0x
2026-08	2552.3x	₹147 cr	0.1%	2.0%	0.0x
2026-07	2643.1x	₹147 cr	0.1%	2.0%	0.0x
2026-06	1826.2x	₹147 cr	0.1%	2.0%	0.0x
2026-05	30.8x	₹144 cr	4.5%	0.0%	0.0x
2026-04	29.1x	₹144 cr	4.5%	0.0%	0.0x
2026-03	22.6x	₹144 cr	4.5%	0.0%	0.0x
2026-02	119.5x	₹131 cr	1.2%	0.0%	0.0x
2026-01	112.5x	₹131 cr	1.2%	0.0%	0.0x
2025-12	124.7x	₹131 cr	1.2%	0.0%	0.0x
2025-11	—	₹126 cr	-0.7%	0.0%	0.0x
2025-10	—	₹126 cr	-0.7%	0.0%	0.0x
2025-09	—	₹126 cr	-0.7%	0.0%	0.0x
2025-08	—	₹115 cr	-0.3%	0.0%	0.0x
2025-07	—	₹115 cr	-0.3%	0.0%	0.0x
2025-06	—	₹115 cr	-0.3%	0.0%	0.0x
2025-05	—	₹102 cr	-3.6%	-1.0%	0.0x
2025-04	—	₹102 cr	-3.6%	-1.0%	0.0x
2025-03	—	₹102 cr	-3.6%	-1.0%	0.0x
2025-02	—	₹98 cr	-1.9%	-1.0%	0.0x
2025-01	—	₹98 cr	-1.9%	-1.0%	0.0x
2024-12	—	₹98 cr	-1.9%	-1.0%	0.0x
2024-11	—	₹97 cr	-0.2%	-1.0%	0.0x
2024-10	—	₹97 cr	-0.2%	-1.0%	0.0x
2024-09	—	₹97 cr	-0.2%	-1.0%	0.0x
2024-08	—	₹95 cr	-1.2%	-1.0%	0.0x
2024-07	—	₹95 cr	-1.2%	-1.0%	0.0x
2024-06	—	₹95 cr	-1.2%	-1.0%	0.0x
2024-05	—	₹112 cr	-4.0%	-5.0%	0.0x
2024-04	—	₹112 cr	-4.0%	-5.0%	0.0x
2024-03	—	₹112 cr	-4.0%	-5.0%	0.0x
2024-02	—	₹112 cr	-4.0%	-5.0%	0.0x
2024-01	—	₹112 cr	-4.0%	-5.0%	0.0x
2023-12	—	₹112 cr	-4.0%	-5.0%	0.0x
2023-11	—	₹112 cr	-4.0%	-5.0%	0.0x
2023-10	—	₹112 cr	-4.0%	-5.0%	0.0x
2023-09	—	₹112 cr	-4.0%	-5.0%	0.0x
2023-08	—	₹112 cr	-4.0%	-5.0%	0.0x
2023-07	—	₹112 cr	-4.0%	-5.0%	0.0x
2023-06	—	₹112 cr	-4.0%	-5.0%	0.0x
2023-05	7.0x	₹256 cr	21.3%	33.0%	0.0x
2023-04	7.4x	₹256 cr	21.3%	33.0%	0.0x
2023-03	6.6x	₹256 cr	21.3%	33.0%	0.0x
2023-02	7.5x	₹256 cr	21.3%	33.0%	0.0x
2023-01	8.5x	₹256 cr	21.3%	33.0%	0.0x
2022-12	11.0x	₹256 cr	21.3%	33.0%	0.0x
2022-11	11.2x	₹256 cr	21.3%	33.0%	0.0x
2022-10	17.1x	₹256 cr	21.3%	33.0%	0.0x
2022-09	19.6x	₹256 cr	21.3%	33.0%	0.0x
2022-08	22.0x	₹256 cr	21.3%	33.0%	0.0x
2022-07	22.6x	₹256 cr	21.3%	33.0%	0.0x
2022-06	21.9x	₹256 cr	21.3%	33.0%	0.0x
2022-05	22.5x	₹213 cr	27.8%	67.0%	0.0x
2022-04	27.9x	₹213 cr	27.8%	67.0%	0.0x
2022-03	29.4x	₹213 cr	27.8%	67.0%	0.0x
2022-02	29.7x	₹213 cr	27.8%	67.0%	0.0x
2022-01	37.3x	₹213 cr	27.8%	67.0%	0.0x
2021-12	43.1x	₹213 cr	27.8%	67.0%	0.0x
2021-11	32.0x	₹213 cr	27.8%	67.0%	0.0x
2021-10	37.2x	₹213 cr	27.8%	67.0%	0.0x
2021-09	34.9x	₹213 cr	27.8%	67.0%	0.0x
2021-08	36.2x	₹213 cr	27.8%	67.0%	0.0x
2021-07	37.1x	₹213 cr	27.8%	67.0%	0.0x
2021-06	34.1x	₹213 cr	27.8%	67.0%	0.0x
2021-05	2.4x	₹99 cr	38.5%	76.0%	0.7x
2021-04	1.9x	₹99 cr	38.5%	76.0%	0.7x
2021-03	—	₹99 cr	38.5%	76.0%	0.7x
2021-02	1.1x	₹99 cr	38.5%	76.0%	0.7x

Methodology and data notes